What is Zacks Research’s Forecast for JAZZ Q1 Earnings?

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) – Zacks Research raised their Q1 2025 earnings per share (EPS) estimates for Jazz Pharmaceuticals in a note issued to investors on Tuesday, March 18th. Zacks Research analyst S. Ganoria now forecasts that the specialty pharmaceutical company will post earnings per share of $3.51 for the quarter, up from their prior forecast of $3.17. The consensus estimate for Jazz Pharmaceuticals’ current full-year earnings is $16.96 per share. Zacks Research also issued estimates for Jazz Pharmaceuticals’ Q2 2025 earnings at $4.70 EPS, Q3 2025 earnings at $5.30 EPS, Q4 2025 earnings at $5.51 EPS, FY2025 earnings at $19.02 EPS, Q1 2026 earnings at $3.13 EPS, Q2 2026 earnings at $4.79 EPS, Q3 2026 earnings at $5.84 EPS, Q4 2026 earnings at $5.90 EPS, FY2026 earnings at $19.66 EPS and FY2027 earnings at $20.50 EPS.

A number of other research analysts have also weighed in on the company. UBS Group upgraded Jazz Pharmaceuticals from a “neutral” rating to a “buy” rating and raised their price objective for the company from $145.00 to $179.00 in a research report on Friday, March 7th. Barclays restated an “overweight” rating and set a $200.00 price objective (up previously from $190.00) on shares of Jazz Pharmaceuticals in a research report on Thursday, February 27th. Royal Bank of Canada cut their price objective on Jazz Pharmaceuticals from $179.00 to $178.00 and set an “outperform” rating for the company in a research report on Wednesday, February 26th. JPMorgan Chase & Co. raised their price objective on Jazz Pharmaceuticals from $200.00 to $209.00 and gave the company an “overweight” rating in a research report on Wednesday, February 26th. Finally, Needham & Company LLC restated a “buy” rating and set a $210.00 price objective on shares of Jazz Pharmaceuticals in a research report on Wednesday, March 5th. One research analyst has rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $187.71.

Jazz Pharmaceuticals Price Performance

NASDAQ:JAZZ opened at $140.57 on Friday. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46. The business’s 50-day simple moving average is $131.07 and its two-hundred day simple moving average is $121.46. The stock has a market cap of $8.54 billion, a PE ratio of 19.80, a P/E/G ratio of 1.04 and a beta of 0.44. Jazz Pharmaceuticals has a 52 week low of $99.06 and a 52 week high of $148.06.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the business. Wealth Enhancement Advisory Services LLC boosted its position in shares of Jazz Pharmaceuticals by 22.1% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 4,102 shares of the specialty pharmaceutical company’s stock valued at $505,000 after buying an additional 743 shares during the period. Mackenzie Financial Corp raised its stake in shares of Jazz Pharmaceuticals by 493.3% during the fourth quarter. Mackenzie Financial Corp now owns 20,286 shares of the specialty pharmaceutical company’s stock valued at $2,498,000 after acquiring an additional 16,867 shares in the last quarter. Forum Financial Management LP bought a new stake in shares of Jazz Pharmaceuticals during the fourth quarter valued at approximately $245,000. GF Fund Management CO. LTD. bought a new stake in shares of Jazz Pharmaceuticals during the fourth quarter valued at approximately $156,000. Finally, MidWestOne Financial Group Inc. raised its stake in shares of Jazz Pharmaceuticals by 10.4% during the fourth quarter. MidWestOne Financial Group Inc. now owns 24,347 shares of the specialty pharmaceutical company’s stock valued at $2,998,000 after acquiring an additional 2,284 shares in the last quarter. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Insider Buying and Selling at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, EVP Neena M. Patil sold 3,800 shares of the business’s stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $144.87, for a total transaction of $550,506.00. Following the completion of the transaction, the executive vice president now owns 33,318 shares in the company, valued at $4,826,778.66. The trade was a 10.24 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Bruce C. Cozadd sold 1,500 shares of the business’s stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $122.31, for a total value of $183,465.00. Following the transaction, the chief executive officer now owns 439,744 shares of the company’s stock, valued at $53,785,088.64. This trade represents a 0.34 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 28,736 shares of company stock worth $4,022,825 over the last 90 days. Company insiders own 4.20% of the company’s stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.